Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials - The Lancet

[unable to retrieve full-text content]

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials  The Lancet

Comments

Popular posts from this blog

William Buoni, MD - Wexner Medical Center

These Are the Top Doctors in the Hudson Valley in 2022

Who are the top doctors in Columbus? Search by specialty with Columbus Monthly's 2021 list